Attacking cancer's aberrant DDR with small molecule inhibitors is a promising route to creating new chemotherapies, as exemplified by the development of PARP inhibitors that received clinical approval for treatment of BRCA deficient cancers.9 To date, most inhibitors have been designed against traditionally “druggable” proteins with the majority targeting the enzyme active sites. This evidence concerns the gene PARP1 and cancer.